These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25934386)

  • 21. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort.
    Gies N; Kroeker KI; Wong K; Fedorak RN
    Aliment Pharmacol Ther; 2010 Aug; 32(4):522-8. PubMed ID: 20500733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.
    Feagan BG; Sandborn WJ; Lazar A; Thakkar RB; Huang B; Reilly N; Chen N; Yang M; Skup M; Mulani P; Chao J
    Gastroenterology; 2014 Jan; 146(1):110-118.e3. PubMed ID: 24067881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Asthma-like symptoms in a patient with rheumatoid arthritis and Adalimumab treatment.
    Mărgineanu I; Crişan R; Mihăescu T
    Pneumologia; 2015; 64(4):28-30. PubMed ID: 27451592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases.
    Siebert S; Tsoukas A; Robertson J; McInnes I
    Pharmacol Rev; 2015; 67(2):280-309. PubMed ID: 25697599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Adalimumab for the treatment of ulcerative colitis--a consensus report by the working group inflammatory bowel diseases of the Austrian Society of Gastroenterology and Hepatology].
    Novacek G; Dejaco C; Knoflach P; Moschen A; Petritsch W; Vogelsang H; Reinisch W
    Z Gastroenterol; 2014 Feb; 52(2):204-11. PubMed ID: 24488763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
    D'Haens G
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S209-16. PubMed ID: 20117344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to?
    Gearry RB; Irving PM
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1160-2. PubMed ID: 19682189
    [No Abstract]   [Full Text] [Related]  

  • 28. [Anti-TNF-alpha antibody treatment of patients with active ulcerative colitis].
    Ainsworth MA; Brynskov J
    Ugeskr Laeger; 2007 Feb; 169(9):789-91. PubMed ID: 17355841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapy of ulcerative colitis].
    Vavricka SR; Rogler G
    Praxis (Bern 1994); 2009 Feb; 98(4):209-12. PubMed ID: 19224489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples.
    Combe B; van Vollenhoven R
    Ann Rheum Dis; 2013 Sep; 72(9):1433-5. PubMed ID: 23625979
    [No Abstract]   [Full Text] [Related]  

  • 31. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
    Baslund B; Bendtzen K
    Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease.
    Ampuero J; Rojas-Feria M; Castro-Fernández M; Cano C; Romero-Gómez M
    J Gastroenterol Hepatol; 2014 Feb; 29(2):291-5. PubMed ID: 23927379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Personalizing therapy for inflammatory bowel diseases.
    Ananthakrishnan AN
    Expert Rev Gastroenterol Hepatol; 2013 Aug; 7(6):549-58. PubMed ID: 23985004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infliximab as therapeutic option in steroid-refractory ulcerative colitis after kidney transplantation: case report.
    Temme J; Koziolek M; Bramlage C; Schaefer IM; Füzesi L; Ramadori G; Müller GA; Schwörer H
    Transplant Proc; 2010 Nov; 42(9):3880-2. PubMed ID: 21094876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combining genetic and nongenetic biomarkers to realize the promise of pharmacogenomics for inflammatory diseases.
    Maranville JC; Di Rienzo A
    Pharmacogenomics; 2014; 15(15):1931-40. PubMed ID: 25495413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis.
    Rismo R; Olsen T; Cui G; Christiansen I; Florholmen J; Goll R
    Scand J Gastroenterol; 2012 May; 47(5):538-47. PubMed ID: 22486187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The safety of biologic agents in the treatment of inflammatory bowel disease.
    Shepela C
    Minn Med; 2008 Jun; 91(6):42-5. PubMed ID: 18616021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A fulminant colitis index greater or equal to 8 is not predictive of colectomy risk in infliximab-treated moderate-to-severe ulcerative colitis attacks.
    Baudet A; Colombel JF; Cortot A; Dupas JL; Brazier F; Savoye G; Lerebours E; Justum AM; Reimund JM
    Gastroenterol Clin Biol; 2010 Nov; 34(11):612-7. PubMed ID: 20832218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Anti-RANKL antibody for the treatment of rheumatoid arthritis].
    Tanaka Y
    Clin Calcium; 2011 Aug; 21(8):1223-9. PubMed ID: 21814029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic and genomic predictors of anti-TNF response.
    Prajapati R; Plant D; Barton A
    Pharmacogenomics; 2011 Nov; 12(11):1571-85. PubMed ID: 22044414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.